Your browser doesn't support javascript.
loading
Inactivated whole virus particle vaccine with potent immunogenicity and limited IL-6 induction is ideal for influenza.
Sekiya, Toshiki; Mifsud, Edin J; Ohno, Marumi; Nomura, Naoki; Sasada, Mayumi; Fujikura, Daisuke; Daito, Takuji; Shingai, Masashi; Ohara, Yuki; Nishimura, Tomohiro; Endo, Masafumi; Mitsumata, Ryotarou; Ikeda, Tomio; Hatanaka, Hironori; Kitayama, Hiroki; Motokawa, Kenji; Sobue, Tomoyoshi; Suzuki, Saori; Itoh, Yasushi; Brown, Lorena E; Ogasawara, Kazumasa; Kino, Yoichiro; Kida, Hiroshi.
Afiliación
  • Sekiya T; Research Center for Zoonosis Control, Hokkaido University, Sapporo, Japan; Global Station for Zoonosis Control, Global Institution for Collaborative Research and Education (GI-CoRE) Hokkaido University, Sapporo, Japan; The Department of Microbiology and Immunology, The University of Melbourne at the
  • Mifsud EJ; Research Center for Zoonosis Control, Hokkaido University, Sapporo, Japan; Global Station for Zoonosis Control, Global Institution for Collaborative Research and Education (GI-CoRE) Hokkaido University, Sapporo, Japan; The Department of Microbiology and Immunology, The University of Melbourne at the
  • Ohno M; Research Center for Zoonosis Control, Hokkaido University, Sapporo, Japan.
  • Nomura N; Research Center for Zoonosis Control, Hokkaido University, Sapporo, Japan.
  • Sasada M; Research Center for Zoonosis Control, Hokkaido University, Sapporo, Japan.
  • Fujikura D; Research Center for Zoonosis Control, Hokkaido University, Sapporo, Japan.
  • Daito T; Research Center for Zoonosis Control, Hokkaido University, Sapporo, Japan.
  • Shingai M; Research Center for Zoonosis Control, Hokkaido University, Sapporo, Japan; Global Station for Zoonosis Control, Global Institution for Collaborative Research and Education (GI-CoRE) Hokkaido University, Sapporo, Japan.
  • Ohara Y; KM Biologics Co. Ltd., Kumamoto, Japan.
  • Nishimura T; KM Biologics Co. Ltd., Kumamoto, Japan.
  • Endo M; KM Biologics Co. Ltd., Kumamoto, Japan.
  • Mitsumata R; R&D Center, Denka Seiken Co., Ltd., Niigata, Japan.
  • Ikeda T; R&D Center, Denka Seiken Co., Ltd., Niigata, Japan.
  • Hatanaka H; The Research Foundation for Microbial Diseases of Osaka University, Kannonji, Kagawa, Japan.
  • Kitayama H; The Research Foundation for Microbial Diseases of Osaka University, Kannonji, Kagawa, Japan.
  • Motokawa K; Manufacturing Department III, Kitasato Daiichi Sankyo Vaccine Co. Ltd., Saitama, Japan.
  • Sobue T; CMC Research Laboratories, Kitasato Daiichi Sankyo Vaccine Co. Ltd., Saitama, Japan.
  • Suzuki S; Division of Pathology and Disease Regulation, Department of Pathology, Shiga University of Medical Science, Otsu, Japan.
  • Itoh Y; Division of Pathology and Disease Regulation, Department of Pathology, Shiga University of Medical Science, Otsu, Japan.
  • Brown LE; Global Station for Zoonosis Control, Global Institution for Collaborative Research and Education (GI-CoRE) Hokkaido University, Sapporo, Japan; The Department of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
  • Ogasawara K; Division of Pathology and Disease Regulation, Department of Pathology, Shiga University of Medical Science, Otsu, Japan; Research Center for Animal Life Science, Shiga University of Medical Science, Otsu, Japan.
  • Kino Y; Kino Consulting, Kumamoto, Japan.
  • Kida H; Research Center for Zoonosis Control, Hokkaido University, Sapporo, Japan; Global Station for Zoonosis Control, Global Institution for Collaborative Research and Education (GI-CoRE) Hokkaido University, Sapporo, Japan; Collaborating Research Center for the Control of Infectious Diseases, Nagasaki Un
Vaccine ; 37(15): 2158-2166, 2019 04 03.
Article en En | MEDLINE | ID: mdl-30857932
In contrast to current ether- or detergent-disrupted "split" vaccines (SVs) for influenza, inactivated whole influenza virus particle vaccines (WPVs) retain the original virus structure and components and as such may confer similar immunity to natural infection. In a collaboration between academia and industry, the potential of WPV as a new seasonal influenza vaccine was investigated. Each of the four seasonal influenza vaccine manufacturers in Japan prepared WPVs and SVs from the same batches of purified influenza virus. Both mice and monkeys vaccinated with the WPVs exhibited superior immune responses to those vaccinated with the corresponding SVs. Vaccination with A/California/07/2009 (H1N1) WPV enabled mice to survive a lethal challenge dose of homologous virus whereas those vaccinated with SV succumbed to infection within 6 days. Furthermore, mice vaccinated with WPV induced substantial numbers of multifunctional CD8+ T cells, important for control of antigenically drifted influenza virus strains. In addition, cytokines and chemokines were detected at early time points in the sera of mice vaccinated with WPV but not in those animals vaccinated with SV. These results indicate that WPVs induce enhanced innate and adaptive immune responses compared to equivalent doses of SVs. Notably, WPV at one fifth of the dose of SV was able to induce potent immunity with limited production of IL-6, one of the pyrogenic cytokines. We thus propose that WPVs with balanced immunogenicity and safety may set a new global standard for seasonal influenza vaccines.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Virión / Vacunas contra la Influenza / Interleucina-6 / Infecciones por Orthomyxoviridae / Anticuerpos Antivirales Límite: Animals / Female / Humans / Male País/Región como asunto: Asia Idioma: En Revista: Vaccine Año: 2019 Tipo del documento: Article Pais de publicación: Países Bajos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Virión / Vacunas contra la Influenza / Interleucina-6 / Infecciones por Orthomyxoviridae / Anticuerpos Antivirales Límite: Animals / Female / Humans / Male País/Región como asunto: Asia Idioma: En Revista: Vaccine Año: 2019 Tipo del documento: Article Pais de publicación: Países Bajos